DNAtrix is a privately held biotech company focusing on the development of oncolytic viruses for cancer. The company’s initial focus is on glioblastoma, a devastating brain tumor that is currently incurable. Since viruses are already good at killing cells, scientists have harnessed this ability by modifying a common cold virus so that it targets and kills cancer cells selectively. Glioblastoma patients have been treated with the cancer-killing virus, called DNX-2401, with excellent early results. The company’s lead product, DNX-2401, is the culmination of more than a decade of scientific and clinical research and is the most potent and effective oncolytic virus delivered to human brain tumors to date. DNAtrix is also working to expand its platform technology for treating other cancers, with unmet medical need. The company has offices located in Houston, Texas and San Diego, California.